Tumor-specific Biomarkers Predict Response in HER-2-positive Breast Cancer

Share this content:
Human epidermal growth factor receptor 2 breast cancers are genetically heterogeneous.
Human epidermal growth factor receptor 2 breast cancers are genetically heterogeneous.

Human epidermal growth factor receptor 2 (HER-2) breast cancers are genetically heterogeneous, and may therefore have biomarkers that will help to develop targeted therapies for patients with breast cancer, according to a study published in JAMA Oncology.1

It is unknown why anti-HER-2 treatments are not equally effective on all cases of HER-2 breast cancer. For the present study, researchers sequenced frozen lesions from the NeoALTTO (Lapatinib with trastuzumab for HER2-positive early breast cancer) study, which investigated the use of dual HER-2 inhibitors for breast cancer treatment.2

Of the 455 patients enrolled to NeoALTTO, 254 frozen samples were sequenced in an attempt to identify useful biomarkers among HER-2-positive patients. The samples were grouped by treatment arm in the NeoALTTO study: 89 for lapatinib, 79 for trastuzumab, and 86 for both.

ERBB2/HER2 and HER2 expression were, according to mRNA sequencing, the best predictors of a pathological complete response. No markers were associated with event-free survival.

RELATED: Q&A With Dr Sarah Vinnicombe: Use Breast MRI Judiciously for Optimal Outcomes

The authors conclude that HER-2-positive cancers are heterogeneous, and that disparate tumor makeup influences the efficacy of anti-HER-2 therapies. The evaluated biomarkers should be considered in future clinical trials, and eventually in real-world practice. Further studies need to confirm these findings.

References

  1. Fumagalli D, Venet D, Ignatiadis M, et al. RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol. 2016 Sep 29. doi: 10.1001/jamaoncol.2016.3824 [Epub ahead of print]
  2. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters